Spectrum Pharmaceuticals (NASDAQ:SPPI) had its price objective raised by HC Wainwright to $33.00 in a report released on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 57.22% from the company’s current price.
Other research analysts have also issued reports about the stock. B. Riley initiated coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, December 18th. They issued a “buy” rating and a $26.00 target price for the company. Guggenheim initiated coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, October 23rd. They issued a “buy” rating and a $32.00 target price for the company. Jefferies Group upped their target price on shares of Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 20th. BidaskClub lowered shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Zacks Investment Research upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.83.
Spectrum Pharmaceuticals (NASDAQ SPPI) opened at $20.99 on Monday. Spectrum Pharmaceuticals has a 1 year low of $4.86 and a 1 year high of $23.50. The stock has a market cap of $2,110.00, a price-to-earnings ratio of -20.99 and a beta of 1.64. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.04 and a quick ratio of 4.89.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.